31/03/2010

Scientific network: recent published results on bindarit

MCP-1/CCL2 is a chemokine that play a major role during inflammatory processes and it has been proposed as a new pharmacological target in several diseases. Bindarit is an Angelini’s original compound effective in reducing MCP-1/CCL2 levels in vitro and in vivo. The following recently published preclinical studies performed in Europe, USA and Australia show that bindarit is active in several experimental conditions where MCP-1/CCL2 play a major role.

Cardiovascular Research 2009 Dec 1; 84(3):485-93
The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice.
Grassia G, Maddaluno M, Guglielmotti A, Mangano G, Biondi G, Maffia P, Ialenti A.
Department of Experimental Pharmacology, University of Naples Federico II, Via Domenico Montesano, 49, 80131 Naples, Italy

Arteriosclerosis Thrombosis and Vascular Biology 2009 Nov; 29(11):1810-6
Monocyte chemoattractant proteins mediate myocardial microvascular dysfunction in swine renovascular hypertension.
Lin J, Zhu X, Chade AR, Jordan KL, Lavi R, Daghini E, Gibson ME, Guglielmotti A, Lerman A, Lerman LO.
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA.

Journal of Hypertension 2009 Oct;27(10):2063-73
The chemokine monocyte chemoattractant protein-1 contributes to renal dysfunction in swine renovascular hypertension.
Zhu XY, Chade AR, Krier JD, Daghini E, Lavi R, Guglielmotti A, Lerman A, Lerman LO.
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA

Arthritis and Rheumatism 2009 Aug;60(8):2513-23
Amelioration of alphavirus-induced arthritis and myositis in a mouse model by treatment with bindarit, an inhibitor of monocyte chemotactic proteins.
Rulli NE, Guglielmotti A, Mangano G, Rolph MS, Apicella C, Zaid A, Suhrbier A, Mahalingam S.
Faculty of Applied Science, University of Canberra, Canberra, ACT, Australia.